{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027344","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.700256+00:00","generated_at":"2026-06-11T21:39:08.769927+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Harrow Q2: record revenue $33.5M (+44% YoY), adj. EBITDA $11.0M (+144%); $69M equity offer, product acquisitions","bullets":["Record revenues of $33.5M, up 44% YoY; GAAP net loss of $4.2M.","Record adjusted EBITDA of $11.0M, up 144% YoY; core gross margin improved to 78% from 73%.","Completed $69M common stock offering and expanded Oaktree loan from $100M to $112.5M.","Acquired North American rights to VEVYE (dry eye drug) and Santen portfolio including FLAREX, NATACYN, TOBRADEX ST.","Reaffirmed 2023 guidance: net revenue $135-143M, adjusted EBITDA $44-50M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027344","json":"https://secwatch.observer/filing/0001493152-23-027344.json","markdown":"https://secwatch.observer/filing/0001493152-23-027344.md","text":"https://secwatch.observer/filing/0001493152-23-027344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315223027344/0001493152-23-027344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315223027344/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:39:08.769927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df447b6b8cf561b19dabddf5e3ce7227471cbcaf","claim":"HARROW, INC. reported financial results for the second quarter and six months ended June 30, 2023.","evidence_excerpt":"On August 9, 2023, Harrow Health, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the period ended June 30, 2023 and an update on recent corporate events.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1360214/000149315223027344/0001493152-23-027344-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter and six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}